阿司匹林用于COVID-19住院患者(RECOVERY):一项随机、对照、开放标签、平台试验
RECOVERY平台试验在177家英国医院、2家印度尼西亚医院和2家尼泊尔医院纳入COVID-19住院成人,1:1随机分配至常规标准治疗加阿司匹林150 mg每日一次至出院(7351例)或单纯常规标准治疗(7541例)。主要终点28天死亡率两组均为17%(率比0.96,95%CI 0.89-1.04;p=0.35),所有预设亚组结果一致。阿司匹林组住院时间略短(中位8天 vs 9天),28天内存活出院比例更高(75% vs 74%;率比1.06,95%CI 1.02-1.10;p=0.0062),血栓事件减少(4.6% vs 5.3%;绝对减少0.6%,SE 0.4%),大出血事件增加(1.6% vs 1.0%;绝对增加0.6%,SE 0.2%)。作者认为阿司匹林未降低28天死亡率或进展至有创机械通气或死亡的风险,仅与28天内存活出院率小幅增加相关。
要点
- COVID-19住院成人使用阿司匹林150 mg每日一次至出院,28天死亡率17% vs 17%(率比0.96,95%CI 0.89-1.04;p=0.35),所有预设亚组结果一致。
- 阿司匹林组28天内存活出院比例75% vs 74%(率比1.06,95%CI 1.02-1.10;p=0.0062),住院时间中位8天 vs 9天。
- 基线未接受有创机械通气的患者中,进展至有创机械通气或死亡的复合终点比例21% vs 22%(风险比0.96,95%CI 0.90-1.03;p=0.23),无显著差异。
- 阿司匹林组血栓事件4.6% vs 5.3%(绝对减少0.6%,SE 0.4%),大出血事件1.6% vs 1.0%(绝对增加0.6%,SE 0.2%)。
适用人群与场景
- 在英国177家医院、印度尼西亚2家医院和尼泊尔2家医院住院的COVID-19成人患者,符合条件并知情同意后随机分配。
- 22 560例入组RECOVERY试验的患者中,14 892例(66%)符合随机分配至阿司匹林的条件。
处置流程与药物剂量
- 阿司匹林组:常规标准治疗加阿司匹林150 mg每日一次,直至出院。
- 对照组:单纯常规标准治疗。
研究设计与关键结果
- 研究类型:随机、对照、开放标签、平台试验;2020年11月1日至2021年3月21日随机分配7351例至阿司匹林、7541例至单纯常规治疗,1:1比例,意向性治疗分析。
- 主要终点28天死亡率:阿司匹林组1222/7351(17%)vs 常规治疗组1299/7541(17%);率比0.96,95%CI 0.89-1.04;p=0.35;所有预设亚组结果一致。
- 28天内存活出院:阿司匹林组75% vs 常规治疗组74%;率比1.06,95%CI 1.02-1.10;p=0.0062;住院时间中位8天(IQR 5至>28)vs 9天(IQR 5至>28)。
- 基线未接受有创机械通气的患者中,进展至有创机械通气或死亡的复合终点:21% vs 22%;风险比0.96,95%CI 0.90-1.03;p=0.23。
- 血栓事件:阿司匹林组4.6% vs 常规治疗组5.3%;绝对减少0.6%,SE 0.4%。
- 大出血事件:阿司匹林组1.6% vs 常规治疗组1.0%;绝对增加0.6%,SE 0.2%。
证据类型、等级与局限
- 证据类型:随机、对照、开放标签、平台试验(RECOVERY),注册号ISRCTN 50189673和ClinicalTrials.gov NCT04381936。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在COVID-19住院患者中,阿司匹林未降低28天死亡率或进展至有创机械通气或死亡的风险,仅与28天内存活出院率小幅增加相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients admitted to hospital with COVID-19.
METHODS: In this randomised, controlled, open-label, platform trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19. The trial took place at 177 hospitals in the UK, two hospitals in Indonesia, and two hospitals in Nepal. Eligible and consenting adults were randomly allocated in a 1:1 ratio to either usual standard of care plus 150 mg aspirin once per day until discharge or usual standard of care alone using web-based simple (unstratified) randomisation with allocation concealment. The primary outcome was 28 day mortality. All analyses were done by intention to treat. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936).
FINDINGS: Between Nov 1, 2020, and March 21, 2021, 14 892 (66%) of 22 560 patients enrolled into the RECOVERY trial were eligible to be randomly allocated to aspirin. 7351 patients were randomly allocated (1:1) to receive aspirin and 7541 patients to receive usual care alone. Overall, 1222 (17%) of 7351 patients allocated to aspirin and 1299 (17%) of 7541 patients allocated to usual care died within 28 days (rate ratio 0·96, 95% CI 0·89-1·04; p=0·35). Consistent results were seen in all prespecified subgroups of patients. Patients allocated to aspirin had a slightly shorter duration of hospitalisation (median 8 days, IQR 5 to >28, vs 9 days, IQR 5 to >28) and a higher proportion were discharged from hospital alive within 28 days (75% vs 74%; rate ratio 1·06, 95% CI 1·02-1·10; p=0·0062). Among patients not on invasive mechanical ventilation at baseline, there was no significant difference in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (21% vs 22%; risk ratio 0·96, 95% CI 0·90-1·03; p=0·23). Aspirin use was associated with a reduction in thrombotic events (4·6% vs 5·3%; absolute reduction 0·6%, SE 0·4%) and an increase in major bleeding events (1·6% vs 1·0%; absolute increase 0·6%, SE 0·2%).
INTERPRETATION: In patients hospitalised with COVID-19, aspirin was not associated with reductions in 28 day mortality or in the risk of progressing to invasive mechanical ventilation or death, but was associated with a small increase in the rate of being discharged alive within 28 days.
FUNDING: UK Research and Innovation (Medical Research Council), National Institute of Health Research, and the Wellcome Trust through the COVID-19 Therapeutics Accelerator.
参考来源
- Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021. PMID: 34800427. doi:10.1016/S0140-6736(21)01825-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。